You just read:

Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis

News provided by

Boston Biomedical, Inc.

Jun 06, 2019, 19:55 ET